{"id":"d0ab5d191e9d","type":"article","url":"https://hartvaat.nl/2026/12/01/lp-a-remmers-verlagen-lipiden-sterk-maar-cardiovasculaire-uitkomst-blijft-onzeke/","title":"Lp(a)-remmers verlagen lipiden sterk, maar cardiovasculaire uitkomst blijft onzeker — HORIZON","title_en":"Lipoprotein(a): Bridging the gap between risk prediction, measurement, and emerging therapeutics.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"International journal of cardiology. Cardiovascular risk and prevention","doi":"10.1016/j.ijcrp.2026.200724","source_url":"https://doi.org/10.1016/j.ijcrp.2026.200724","authors":["Waseem Abbas","Ashir Kanwal","Shifaullah Mian","Fazil Ali Syed","Shah Rukh","Habeeb Ahmad","Muhammad Salaar Aijaz","Muhammad Mudasir","Sara Collins","Samuel Amin","Mohammed Hammad Jaber Amin"],"significance":7,"published":"2026-11-17","source_date":"2026-12-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"This narrative review examines Lipoprotein(a) [Lp(a)] as a causal risk factor for atherosclerotic cardiovascular disease, highlighting ongoing challenges in assay standardization and clinical screening. While novel antisense oligonucleotides and siRNA therapies achieve sustained Lp(a) reductions exceeding 80%, recent phase 3 data from the Lp(a)HORIZON trial demonstrate that substantial lipid lowering does not automatically translate into fewer cardiovascular events. These findings underscore the need for validated treatment thresholds, standardized testing, and definitive outcome trials before Lp(a)-directed therapies can be integrated into routine cardiovascular prevention.","created":"2026-11-11T02:07:07Z","updated":"2026-11-11T02:07:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Deze narratieve review belicht de rol van Lipoproteïne(a) [Lp(a)] als causaal risicofactor voor atherosclerotische cardiovasculaire ziekte en de huidige uitdagingen rondom screening en standaardisatie van metingen. Nieuwe therapeutische strategieën, waaronder antisense-oligonucleotiden en siRNA’s, reduceren Lp(a)-concentraties met meer dan 80% in eerdere fasen, maar recente fase-3 resultaten van Lp(a)HORIZON tonen aan dat deze sterke lipiddaling niet automatisch leidt tot minder cardiovasculaire gebeurtenissen. Voor de klinische praktijk betekent dit dat standaardisatie van assays, vaststelling van behandel-drempelwaarden en afwachten van definitieve uitkomstgegevens cruciaal zijn voordat Lp(a)-remmers routinematig kunnen worden ingezet.","abstract_original":"Lipoprotein(a) [Lp(a)] is a genetically determined lipoprotein and a well-established causal risk factor for atherosclerotic cardiovascular disease (ASCVD). Despite increasing recognition in clinical guidelines, Lp(a) testing remains underused, and targeted therapies are only now emerging. This narrative review summarizes the biology, cardiovascular risk, measurement challenges, emerging therapies, and translational barriers of Lp(a), highlighting its role in contemporary cardiovascular prevention. Lp(a) promotes cardiovascular disease through pro-atherogenic, pro-inflammatory, and prothrombotic mechanisms mediated by lipid deposition, oxidized phospholipids, and impaired fibrinolysis. Elevated Lp(a) independently predicts coronary artery disease (CAD), ischemic stroke, peripheral artery disease, and calcific aortic valve disease across diverse populations. However, widespread clinical implementation is limited by apo(a) isoform heterogeneity, assay variability, inconsistent reporting in mg/dL and nmol/L, and low testing rates despite recommendations for once-in-a-lifetime screening. Novel Lp(a)-targeted therapies, including antisense oligonucleotides, small interfering RNAs, and the oral small-molecule inhibitors, have demonstrated sustained reductions in Lp(a) concentrations exceeding 80% in early-phase clinical trials, with favorable safety profiles. Lp(a) is an important residual cardiovascular risk factor with promising targeted therapeutic options. However, important translational gaps remain, including assay standardization, validated treatment thresholds, and definitive cardiovascular outcome data. Recent Lp(a)HORIZON phase 3 evidence has shown that substantial Lp(a) lowering does not necessarily reduce cardiovascular events, while other ongoing phase 3 outcome trials will further determine whether Lp(a)-lowering therapies improve clinical outcomes and establish their role in routine cardiovascular prevention."}